Potential risks of generative artificial intelligence in kidney care
Clicks: 20
ID: 321470
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
5.7
/100
20 views
6 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #19 of 150 articles by views in clinical kidney journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 150 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Generative artificial intelligence (GenAI), particularly large language models, is rapidly emerging as a transformative tool in medicine, including nephrology, with applications spanning clinical decision support, documentation, patient education, and research. Unlike traditional machine learning systems, GenAI produces probabilistic, context-dependent outputs, introducing novel opportunities but also distinct risks. This review examines key risk domains associated with the integration of GenAI into kidney care. These include data-related challenges such as bias, limited representativeness, and data quality issues; technical limitations such as hallucinations and prompt-dependent variability; and cognitive risks, including automation bias and overreliance. The differences between human clinical reasoning and AI-generated outputs further complicate safe implementation, particularly in high-stakes decision-making contexts. In addition, broader systemic concerns are addressed, including inequities in access, linguistic and infrastructural disparities, and the environmental footprint associated with large-scale AI systems. We highlight that these risks are not isolated but interconnected, with potential implications for patient safety, clinical decision-making, and health system equity. While GenAI may enhance efficiency and support clinical workflows, its outputs require critical appraisal and validation within the clinical context. Safe and responsible implementation will depend on a combination of technical safeguards, structured prompting, rigorous validation, and human-in-the-loop oversight. Regulatory frameworks provide an essential foundation, but clinical accountability remains central. Ultimately, the integration of GenAI in nephrology should prioritize safety, equity, and sustainability, ensuring that technological innovation translates into meaningful and responsible improvements in patient care.
| Reference Key |
openalex_W7169611824
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Elizabeth R Viera Ramírez, Leonor Fayos de Arizón, Roser Torrá, Gabriel de Maeztu |
| Journal | clinical kidney journal |
| Year | 2026 |
| DOI |
10.1093/ckj/sfag200
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.